Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 May 2023 | Story Leonie Bolleurs | Photo Supplied
Prof André Roodt
Prof Andreas Roodt was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns. He will receive the prize, sponsored by Sanlam, at a function scheduled for September this year.

Prof Andreas Roodt, former Head of the Department of Chemistry at the University of the Free State (UFS) and retired Distinguished Professor in the same department, was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns.

The prize, a major recognition of his life's work, was presented to him for his contribution to the exploration and sustained development of natural science and technology and the successful application thereof in broader society.

Impacting society

About receiving the prize, he says it was a big surprise, but he is very proud to be honoured with this special award, “being an Afrikaans kid from a ‘platteland’ school outside Bloemfontein.”

Prof Roodt’s research focuses on understanding the reaction mechanisms of mainly inorganic coordination chemical systems that are critical to different industrial, medical, environmental, and metal beneficiation processes.

His research, for instance, contributes to important compounds and processes relevant to nuclear medicine and potential cancer therapy. Not so long ago, he registered a patent on this in Europe, Japan, and the USA that could help to diagnose and potentially treat cancer-related tumours in the future.

In addition, he continues to work on several projects aimed at developing cleaner industrial processes in the South African petrochemical industry. He is also focusing on more efficient ways of accessing the country’s mineral resources.

Career highlights

Throughout his academic career, Prof Roodt has achieved many significant milestones. He was extensively involved in crystallography for more than 30 years. One of his career highlights was being elected as the President of the European Crystallographic Association from 2012 to 2015, an organisation with more than 35 member countries.

In this field, he established an X-ray crystallographic facility in the UFS Department of Chemistry, which was officially named the ‘Roodt XRD Lab’ at the end of 2021.

He also sees his journey with the diverse group of 41 PhD and 54 MSc students (Afrikaans, English, Sesotho, Setswana, and isiXhosa) as another notable achievement in his career.

Other outstanding moments in Prof Roodt's career were his collaborations with research leaders from countries such as the USA, UK, Switzerland, Italy, Sweden, France, Croatia, India, Japan, Russia, the Netherlands, Germany, and Tunisia. These collaborations have allowed him to be recognised by peers worldwide and have demonstrated that Africa and South Africa can produce high-quality and relevant research that can compete on an international level.

The future

Despite his appointment as a Distinguished Professor and his commitment to finishing uncompleted work and assisting younger colleagues both in South Africa and abroad, Prof Roodt retired more than a year ago. He is now enjoying his retirement with his wife, children, and grandchildren, while also devoting time to his passion for collecting aloe plants and generating new hybrids.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept